Member Info for ShearClass

Sure - scroll down to the comments section - it's in response to Fit York Mum's question...

https://www.linkedin.com/feed/update/urn:li:activity:6664062936106967040

Posted by the CEO of Aptamer Group on Linkedin 8 hours ago:

"Hello, we are developing the reagents to detect the virus itself. Aptamer’s can be used to replace and antibody in an antibody type test. Think of a pregnancy test kit - that is an antibody test.

Here we would replace the antibody (that recognises the molecule found in urine that determines that you are pregnant) with an Aptamer that tells you if you have COVID19.

The tests on the news, the antigen tests, test a blood sample for the presence of antibodies against COVID19. If you have previously had COVID your body may generate antibodies it uses to ‘fight’ the virus. These can be detected on these tests."

Moving nicely now, could easily see a close in the 40's if the seller is done / consolidation complete.

Ask rising again after a small amount of buying...reckon we could see a recovery into close, panicky sellers who hadn't done their research have hopefully been rinsed out now!

Seen it before on so many shares - GDR was taken from £1 on the last Cytiva RNS down to 65p before motoring back up the following week. A 35% retracement from the 50p seen yesterday morning is 32.5p, so I expect this will be close to the bottom. Once you understand the facts here it is a compelling hold at this level - the wider market is clearly still unaware / sleeping at present!

https://www.aptamergroup.co.uk/find-out-more/partnerships/

Of most relevance is that Payaytec are the lead organisation in the partnership:

Competition Title: Technology Strategy Board CR&D Competition
Project Title: Novel Use of Aptamers and UV Area Imaging for Disease Detection
Lead Organisation: Paraytec
Total Grant Awarded: £149,632

This project brings together the innovative detection technology of Paraytec Ltd with the target recognition technology provided by Aptamer Diagnostic Ltd to create the next generation of detection instruments. These novel platforms will allow rapid field and point-of-care diagnosis based on multiplex detection of markers of disease or contamination. Simultaneous detection of multiple markers will reduce the ambiguity associated with diagnostic systems which look for single markers. It will also save both time and expense associated with routine laboratory based sample screening, allowing them to focus on samples where more detailed analysis is required.

Only just over 3m shares issued in both placings, so overhang shouldn’t last long. Hard to believe this won’t reach £20m market cap minimum this month which would be 66p. £1 just £30m market cap...

Can currently sell above the ask... tells you everything about where this is heading today. Back to 40p + by close IMO

https://www.linkedin.com/pulse/high-affinity-reagents-developed-covid-19-s1-rbd-protein-arron-tolley

Read this and try not to get excited... Paraytec which are 100% owned by BRH seem integral to the process. Exciting times ahead here.

Clearly the business is in a completely different place now to the figures that will be released in the 2019 final results, and I’d expect the commentary to focus on the transformation that has taken place in the first half of 2020 & how this will impact the business going forwards.

Graham Mullis has proven himself to be a master communicator to date & I think next week will evidence this strength again. I doubt we’ll get EBITDA guidance, but it will be an exceptionally positive report & one j am very much looking forwards to reading.

Huge buying in France, up to 4.81!

France has just started to rocket...big buys coming in.

Interesting that GDR have disclosed commercials on their PCR test in this mornings placing RNS:

"On 20 April 2020, genedrive announced that it had entered into a development agreement with Cytiva (formerly GE Healthcare Life Sciences) to allow for high throughput manufacturing of over 10,000 tests per hour. genedrive has also secured sufficient supply chain commitments for the most critical components to enable the manufacturing of six million tests. The Company anticipates launching the Genedrive(R) 96-SARS-CoV-2 in May 2020 at an estimated price of GBP8-10 per test. The Company will address the market on a non-exclusive basis with sales through an appropriate mix of distributors and direct to customers. The Directors believe that based on its sales volume forecasts and estimates of selling prices in the market, the Company will be able to achieve attractive gross margins of at least 60%, noting genedrive does not fully absorb labour costs into its margins."

So I think it's safe to assume our selling price & gross margins are at least the same as GDR propose. So of the £90m revenue, we are looking at a minimum gross profit of £54m to 28th April...

Yes the £100m valuation looks very anomalous compared to the Covid-19 testing shares, I suspect that this will change over the coming weeks!

Lowest share price since 2000 here today...must be a big sell in the background.

AVCT is a ticking time bomb until it proves that it’s test works with 100% accuracy & has it CE marked, FDA EUA approved & all of the other regulatory approvals it will need to be allowed to sell the test.

There is also plenty of evidence as to why a 10 minute self test won’t provide greater than 95% sensitivity, which quite frankly isn’t good enough in the current situation. AVCT will be a bloodbath if there is even the slightest whiff of this being the case.

NCYT on the other hand is gold standard in specificity & sensitivity, hence why it was chosen by the DHC to fulfil the next 6 months of test requirements.

Tipped by Glasshalffull on Twitter, worth a look based on today’s positive results + the recent fall of 40% from early March.

Truly extraordinary and incredibly pathetic to waste time writing something so banal & laden with passive aggressive intent. You need anger management classes, as well as investing lessons as you are clearly furious to have missed a 4000% rise! Ps. 99.9% of investors bought at 30p+ so have only enjoyed a 1400% rise to date... ha.

Interesting to compare the share price action on 8th April (day we got 3 x RNS’s including the GSK / Astra collaboration. It opened at £2.60 and closed at £2.60, a rise of 16%. Clearly it was held up by a large sell or something.

The following day we saw a meteoric rise to £5.20 as the news was digested properly... I wonder if we’ll see similar price behaviour tomorrow, as a 12% rise doesn’t match the scale of today’s news IMO.

I expect that the next RNS will be an update on the opening of the SuperLab at Cambridge & our work with AZN / GSK. It wouldn’t surprise me in the slightest if this arrives tomorrow am.